Voloridge Investment Management, LLC Zentalis Pharmaceuticals, Inc. Transaction History

Voloridge Investment Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$9.84 - $20.13 $1.73 Million - $3.53 Million	175,537 New	175,537 $2.66 Million
Q1 2023 May 15, 2023	BUY	$16.14 - $24.94 $30,569 - $47,236	1,894 Added 1.3%	147,923 $2.54 Million
Q4 2022 Feb 14, 2023	SELL	$18.07 - $25.6 $1.15 Million - $1.62 Million	-63,405 Reduced 30.27%	146,029 $2.94 Million
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $1.42 Million - $2.22 Million	-70,076 Reduced 25.07%	209,434 $4.54 Million
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $2.64 Million - $7.71 Million	147,570 Added 111.85%	279,510 $7.85 Million
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $1.96 Million - $3.8 Million	47,028 Added 55.38%	131,940 $6.09 Million
Q4 2021 Feb 14, 2022	BUY	$66.92 - $84.79 $2.52 Million - $3.19 Million	37,590 Added 79.43%	84,912 $7.14 Million
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $946,340 - $1.49 Million	20,208 Added 74.53%	47,322 $3.15 Million
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $1.01 Million - $1.69 Million	27,114 New	27,114 $1.44 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $166M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Voloridge Investment Management, LLC with notifications on news.